Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 1999

View Archived Issues

Piracetam approved in Japan for cortical myoclonus Rx

Isis presents clinical data at AACR-NCI-EORTC meeting; Novartis withdraws from collaboration

British Biotech makes tangible progress during past six months

MonteGen offers potent antithrombotic agent for licensing

Biomatrix regains exclusive marketing rights to Synvisc in Canada

Cel-Sci begins cancer collaboration in Germany

Dynavax and Stallergenes to develop seasonal allergy therapy

Biomira enters collaborative agreement, licenses two patents for cancer vaccine

GlycoDesign and Seikagaku collaborate on antiinflammatory drugs

Enrollment completed in Inflammatics' phase I/II trial of LeukoVAX in RA

Schering AG will handle marketing and sales of Levulan for Dusa; U.S. launch in sight

Tularik reviews T-138067 clinical data and presents new related compound

Water-soluble paclitaxel derivatives developed at Canadian university

Vertex continues to search for new IMP dehydrogenase inhibitors

Bacterial enzyme inhibitors described by SB

Pfizer discloses modulators of cholinergic function for smoking cessation, etc.

Orally bioavailable sPLA2 inhibitor designed at Lilly

Novel fibrinolytics recently patented by ADIR

L-158809-loaded microspheres assessed in rat model for ability to inhibit restenosis

D-0870-loaded nanospheres highly effective in mouse model of Chagas' disease

Lack of PK interaction between Ziracin and gentamicin demonstrated in humans

Topical formulations of ABT-281 in development according to 1999 AAPS presentations

Animal pharmacokinetics and metabolism of OSU-6162 characterized

Lundbeck presents enhanced R&D pipeline; company will not market Parkinsan outside Germany

Coadministration of betamipron may reduce risk of nephrotoxicity with tenofovir DF

Clinical trials with IDEC-114 begin following favorable safety and pharmacokinetic results in chimps

Ortho-McNeil to acquire Cygnus drug delivery assets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...